JAGX - Jaguar Health Inc Stock Price, Fair Value and News

$1.01-0.15 (-12.93%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

JAGX Price Action

Last 7 days

-21.1%

Last 30 days

-45.4%

Last 90 days

-38.8%

Trailing 12 Months

-96%

JAGX RSI Chart

JAGX Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.04

Price/Sales (Trailing)

0.13

EV/EBITDA

0.05

Price/Free Cashflow

-0.06

JAGX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

JAGX Fundamentals

JAGX Revenue

Revenue (TTM)

11.8M

Rev. Growth (Yr)

-0.8%

Rev. Growth (Qtr)

3.49%

JAGX Earnings

Earnings (TTM)

-40.3M

Earnings Growth (Yr)

3.57%

Earnings Growth (Qtr)

8.7%

JAGX Profitability

Operating Margin

81.92%

EBT Margin

-348.22%

Return on Equity

-924.36%

Return on Assets

-81.45%

Free Cashflow Yield

-1.7K%

JAGX Investor Care

Shares Dilution (1Y)

303.72%

Diluted EPS (TTM)

-44.79

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	11.6M	11.8M	11.8M	0
2024	10.0M	10.2M	10.5M	11.7M
2023	11.4M	10.9M	10.3M	9.8M
2022	6.2M	8.1M	10.1M	12.0M
2021	0	0	0	4.3M
2020	5.1M	6.5M	8.3M	9.4M
2019	5.2M	6.0M	5.9M	5.8M
2018	4.3M	4.3M	4.4M	4.4M
2017	925.8K	1.8M	2.8M	4.4M
2016	234.1K	195.1K	167.8K	141.5K
2015	0	0	0	258.4K

Get all data in R, Python etc through our Historical Stock Data APIs

About Jaguar Health Inc

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

CEO	Ms. Lisa A. Conte
WEBSITE	https://jaguar.health
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	60

Jaguar Health Inc Frequently Asked Questions

What is the ticker symbol for Jaguar Health Inc? What does JAGX stand for in stocks?

JAGX is the stock ticker symbol of Jaguar Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jaguar Health Inc (JAGX)?

As of Wed Dec 03 2025, market cap of Jaguar Health Inc is 1.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JAGX stock?

You can check JAGX's fair value in chart for subscribers.

Is Jaguar Health Inc a good stock to buy?

The fair value guage provides a quick view whether JAGX is over valued or under valued. Whether Jaguar Health Inc is cheap or expensive depends on the assumptions which impact Jaguar Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JAGX.

What is Jaguar Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, JAGX's PE ratio (Price to Earnings) is -0.04 and Price to Sales (PS) ratio is 0.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JAGX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Jaguar Health Inc's stock?

In the past 10 years, Jaguar Health Inc has provided -0.841 (multiply by 100 for percentage) rate of return.